Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 7Phase 3 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 2Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 4pembrolizumab 2Radiotherapy 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2Ipilimumab 2Cyclophosphamide 2tislelizumab 1teprotumumab 1pazopanib 1lenvatinib 1gallium citrate 1fludarabine phosphate 1fludarabine 1evolocumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1cabozantinib 1auricularum 1aldesleukin 1Spectrum Analysis 1Specimen Handling 1Pemetrexed 1Oxymorphone 1Oxycodone 1Nivolumab 1Morphine 1Levorphanol 1Lapatinib 1Hydromorphone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasm Metastasis × pazopanib × Clear all
NCT01221506 2020-03-26

Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡